|
||
| Gilenya News Channel |  |
|
|
|||||
|
|||||
|
|||||
| MS NEWS ARCHIVES: by week | |||||
| July 2013 | |||||
| September 2013 | |||||
| October 2013 | |||||
| June 2014 | |||||
| July 2014 | |||||
| January 2015 | |||||
| February 2015 | |||||
| March 2015 | |||||
| April 2015 | |||||
| May 2015 | |||||
| July 2015 | |||||
| March 2016 | |||||
| April 2016 | |||||
| May 2016 | |||||
| June 2016 | |||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
 |
|||||
| HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS | |||||
 |
|||||
| |||||
| |||||
 Click to view 1280 MS Walk photos! | |||||
|
|||||
|
|||||
|
|||||
Sunday
Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR
Teva
soaring out in front on a single product and it is no surprise that the
Generics pack are waiting in the rear ready for the copaxone patents to
expire starting May 2014. However Biogen are backing the most winners
with a staggering $5.8 billion worth of business. #2 Avonex Biogen Idec $3.0 billion
#3 Gilenya Novartis $1.9 billion
#4 Tysabri Biogen Idec $1.7 billion
#5 Betaseron Bayer $1.1 billion
#6 Tecfidera Biogen Idec $0.9 billion
#7 Rebif EMD serono $0.6 billion
#8 Ampyra Biogen Idec $0.3 billion
#9 Aubagio Sanofi $0.2 billion
#10 Extavia Novartis $0.2 billion
Read more »
Labels: 20 Best Stories & Studies, Ampyra, Aubagio, Avonex, Betaseron, Copaxone, Extavia, Rebif, Tecfidera, Tysabri
Saturday
HOW MS MEDICATIONS DIFFER FROM EACH OTHER
Read more »
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Novantrone, Rebif, Tecfidera, Tysabri
Synthetic Biologics Announces Issuance of U.S. Patent patents for MS and other autoimmune diseases covering the uses of its oral estriol candidate, Trimesta
FREE MS RESEARCH UPDATE: a comprehensive overview of research findings on all of the FDA-approved disease-modifying therapies, as well as many experimental treatments
This year's expanded MS Research Update incorporates new information about the approved disease-modifying therapies (DMTs), as well as numerous experimental drugs currently under investigation for the long-term treatment of multiple sclerosis (MS). Highlights and recent research results are provided for each drug. Please note that symptom-management drugs are not included in this report.
DOWNLOAD YOUR FREE PDF OR ORDER A FREE COPY
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Lemtrada, Rebif, Rituxan, Tecfidera, Tysabri
Friday
Daniel Kantor, MD, on Specialty Pharmacy in Multiple Sclerosis
In
the last two decades we’ve seen really an explosion of the treatments
we have for multiple sclerosis (MS),” said Daniel Kantor, MD, medical
director, Neurologique, immediate past president, Florida Society of
Neurology. Until recently, self-injectables and intravenous medications
were the only treatment options available for patients diagnosed with MS
making specialty pharmacy, “hugely important for the treatment of MS.”
Today, there are 10 disease-modifying agents approved by the US Food and
Drug Administration:
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Daniel-Kantor-MD-on-Specialty-Pharmacy-in-Multiple-Sclerosis-#sthash.qllKQSe0.dpuf
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Novantrone (mitoxantrone)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
Dr
Kantor notes that specialty pharmacies ensure facilities and patients
receive medications in a timely manner. Specialty pharmacies also play a
crucial role in both patient education and adherence.
“In
the last two decades we’ve seen really an explosion of the treatments
we have for multiple sclerosis (MS),” said Daniel Kantor, MD, medical
director, Neurologique, immediate past president, Florida Society of
Neurology. Until recently, self-injectables and intravenous medications
were the only treatment options available for patients diagnosed with MS
making specialty pharmacy, “hugely important for the treatment of MS.”
Today, there are 10 disease-modifying agents approved by the US Food and
Drug Administration:
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Daniel-Kantor-MD-on-Specialty-Pharmacy-in-Multiple-Sclerosis-#sthash.qllKQSe0.dpuf
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Novantrone (mitoxantrone)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
Dr
Kantor notes that specialty pharmacies ensure facilities and patients
receive medications in a timely manner. Specialty pharmacies also play a
crucial role in both patient education and adherence.
“In
the last two decades we’ve seen really an explosion of the treatments
we have for multiple sclerosis (MS),” said Daniel Kantor, MD, medical
director, Neurologique, immediate past president, Florida Society of
Neurology. Until recently, self-injectables and intravenous medications
were the only treatment options available for patients diagnosed with MS
making specialty pharmacy, “hugely important for the treatment of MS.”
Today, there are 10 disease-modifying agents approved by the US Food and
Drug Administration:
- See more at:
http://www.ajmc.com/conferences/ectrims2013/Daniel-Kantor-MD-on-Specialty-Pharmacy-in-Multiple-Sclerosis-#sthash.qllKQSe0.dpuf
- Aubagio (teriflunomide)
- Avonex (interferon beta-1a)
- Betaseron (interferon beta-1b)
- Copaxone (glatiramer acetate)
- Extavia (interferon beta-1b)
- Gilenya (fingolimod)
- Novantrone (mitoxantrone)
- Rebif (interferon beta-1a)
- Tecfidera (dimethyl fumarate)
- Tysabri (natalizumab)
Dr
Kantor notes that specialty pharmacies ensure facilities and patients
receive medications in a timely manner. Specialty pharmacies also play a
crucial role in both patient education and adherence.
See Video Here
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Novantrone, Rebif, Tecfidera, Tysabri
Multiple Sclerosis Market (MS) Trends & 2018 Forecasts in New Study at MarketReportsOnline.com
Dallas, TX -- (SBWIRE) -- 11/29/2013 --
The report titled "Global Multiple Sclerosis Market: Trends &
Opportunities (2013-18)" provide an insight into the market dynamics and
various trends and opportunities associated with the global multiple
sclerosis market. The report analyzes the various causes and symptoms
related to the prevalence of MS in patients. Further, the report
analyzes the global market sizing and growth of multiple sclerosis in
terms of revenue, number of patients and sales of effective drugs. Also,
the domestic market of United States which is the largest contributor
to the global multiple sclerosis market has been assessed. The report
concludes with a brief discussion of major factors driving the global
multiple sclerosis market and profiles major players like Teva, Biogen
Idec, Merck KGaA, Bayer and Novartis.
The global Multiple Sclerosis market is undergoing drastic change since
the last few years. The rising diagnosis and treatment rate coupled with
growing investment in research and development has played a key role in
the determining the growth dynamics of the global Multiple Sclerosis
(MS) market.
Currently, MS is known to affect an estimated 2.5 million people around
the world with around 5000 new cases emerging each year. Since there is
no particular cure or treatment for multiple sclerosis, the market is
currently dominated by few drugs and medication like Copaxone, Avonex,
Betaseron and Extavia which delay or reduce the progression of multiple
sclerosis in individuals.
Read more »
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia
How Multiple Sclerosis Is Treated
Now that you finally have a name -- multiple sclerosis -- to match the symptoms that have been plaguing you, you've probably got a lot of questions about how to treat those symptoms and keep your condition from getting worse. Although researchers haven't yet discovered a cure for MS, there are many effective medications to help manage your disease. Your doctor will work closely with you to find the treatment that works best for you while causing the fewest side effects.
Here is a rundown of your MS treatment options.
Changing the Course of Your MS: The Disease-Modifying Drugs
Read more »
Labels: Aubagio, Avonex, Betaseron, Copaxone, Extavia, Novantrone, Rebif, Tecfidera, Tysabri